Buy Rating for Mereo Biopharma Group Plc Driven by Promising Phase 3 Study of Setrusumab in Osteogenesis Imperfecta

TipRanksApr 24 14:35 ET · Ratings

Mereo BioPharma Group Plc (MREO): A Bull Case Theory

Yahoo FinanceApr 16 15:00 ET

Cantor Fitzgerald Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsMar 27 14:31 ET · Ratings

Mereo Wins New Overweight at J.P. Morgan Ahead of Trial Readouts

Seeking AlphaMar 27 11:38 ET

European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading

MT NewswiresMar 27 11:21 ET

This Roper Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaMar 27 08:52 ET